Immuneering Corporation

NASDAQ:IMRX

Biotechnology

Healthcare
$3.50 -0.14%

-$0.01 today

Market cap
$226.67M
Beta
0.38
P/E (TTM)
-3.6
EPS (TTM)
-$1.24
52W Low $2.29High $10.08

Volume 0.73M

Average 1.38M

IMRX Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Immuneering CorporationNASDAQ: IMRX

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables outflow grows to $0

Q1 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How IMRX compares with its peers on the latest reported figures

  • IMRX's LTM Mar 2026 accounts receivables of $0 is the 8th largest of the 11 companies compared; the peer median is $0.
IMRX Competitors Peer median
Accounts Receivables for IMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$32.8M +4000.1%+39.1%47.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$13.31M +6.6%—29.4%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$10.63M ——4723.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$3M -137.5%—21.6%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$1.26M -98.3%—21.9%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$451K -1148.8%+17.0%0.6%
HUMAHumacyte, Inc.LTM Mar 2026$54K +117.5%—2.7%
IMRXImmuneering CorporationLTM Mar 2026$0 ———
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 ———
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 ——0.0%
ZURAZura Bio LimitedLTM Mar 2026$0 ———
Peer median (excluding IMRX) $0-45.8%+28.1%21.8%

Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.54M)(50.51M)(53.47M)(61.04M)(56.02M)
Depreciation & Amortization159.07K796.79K352.08K385.07K698.89K
Deferred Income Tax(307.49K)0000
Stock-Based Compensation1.8M05.73M6.5M0
Change in Working Capital900.42K1.72M(974.64K)(925.38K)3.82M
Accounts Receivables279.71K233.62K12.42K00
Inventory00000
Accounts Payables(130.4K)1.76M(1.11M)(112.14K)(400.8K)
Other Working Capital751.1K(276.56K)119.84K(813.24K)4.22M
Other Non-Cash Items130.24K3.9M(601.59K)75.98K6.16M
Operating Cash Flow(30.85M)(44.1M)(48.97M)(55M)(45.34M)
Capital Expenditures(60.79K)(742.49K)(342.75K)(84.88K)(142.23K)
Acquisitions (Net)70.35K0000
Purchases of Investments(75.63M)(50.1M)(44.66M)(5.41M)(88.6M)
Sales of Investments75.62M92.68M52.3M31.93M0
Other Investing Activities(75.62M)000247
Investing Cash Flow(75.62M)41.83M7.3M26.43M(88.74M)
Debt Repayment00000
Common Stock Issued120.32M19K28.2M4.24M226.58M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(842.76K)0241.07K1.07M(147)
Financing Cash Flow144.26M19K28.44M5.3M226.58M
Effect of Forex Changes00000
Net Change in Cash37.8M(2.25M)(13.23M)(23.26M)92.5M
Free Cash Flow(30.91M)(44.84M)(49.31M)(55.08M)(45.49M)

Immuneering Corporation

NASDAQ:IMRX

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.